New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
You may also be interested in...
With top-line data showing efficacy in type 1 SMA patients, risdiplam may be able to obtain a label that would address significantly more patients than Novartis’ Zolgensma. Final efficacy data will show how drug’s efficacy compares to Biogen’s Spinraza.
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
In a collaboration with Ionis Pharmaceuticals, Bayer is pressing ahead with Phase II clinical studies of an antisense molecule designed to reduce Factor XI production and prevent thrombosis.